|
Syndromic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MECP2
|
|
Starts or inhibits transcription; neuron maturation; regulated by development |
|
+ |
+ |
+ |
+ |
+ |
|
M |
+ |
+ |
+ |
– |
+ |
|
One copy knocked out of Crh, or Crhr1, or Oprm; Reducing Mecp2 expression from a transgene, MECP2-dNIC; Reinstatement of Mecp2 |
|
7,8-Dihydroxyflavone; Acetyl-L-carnitine; D-Cycloserine; CX546; Antalarmin; Cysteamine; RU-486; Isoguvacine; Midazolam; Fenobam; SCH-23390; SCH-39166 |
|
Achilly et al., 2021; Zhan et al., 2021
|
|
|
|
|
|
|
|
|
R |
+ |
+ |
+ |
+ |
+ |
|
|
|
|
|
|
|
|
|
|
|
F |
+ |
+ |
+ |
– |
+ |
|
|
|
|
|
|
|
|
|
|
|
I |
+ |
+ |
+ |
– |
+ |
|
|
|
|
FMR1
|
|
Involves in translation; affects neuronal proliferation and migration |
|
+ |
+ |
+ |
+ |
+ |
|
R |
+ |
+ |
+ |
+ |
+ |
|
Inactivation of one allele of App gene; inactivation of one copy of S6K1; inactivation of S6K1 gene |
|
Cyclosporine-A; Dexpramipexole; Isoguvacine; CTEP; Bryostatin1; MPEP; BW-723C86; MDL-11,939; JQ1; Sulpiride; CX-4945, Recombinant IL-17a, Lithium; Minocycline; Lipopolysaccharide; Bumetanide; FRAX486 |
|
Dockendorff et al., 2002; Kim et al., 2014b; Reynolds et al., 2021; Schiavi et al., 2020
|
|
|
|
|
|
|
|
|
F |
+ |
+ |
+ |
– |
+ |
|
|
|
|
|
|
|
|
|
|
|
I |
+ |
+ |
+ |
– |
+ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SHANK3
|
|
Promotes formation, maturation, and stability of dendritic spines |
|
+ |
+ |
+ |
+ |
+ |
|
M |
+ |
+ |
+ |
– |
+ |
|
Reinstatement of Shank3; beta-catenin shRNA; constitutively active Rac1 |
|
CDPPB; MPEP; Insulin-like growth factor 1 and its peptide derivative; CX-546; Lipopolysaccharide; Cocaine; Isoguvacine; D-Cycloserine; 7,8-Dihydroxyflavone; TG003; Valproic acid; Aripiprazole; Clozapine; Romidepsin; Fluoxetine; Phospho-cofilin peptide; Oxytocin; Risperidone; Trichostatin A |
|
Han et al., 2013; Kozol et al., 2015; Liu et al., 2018; Matas et al., 2021; Mossa et al., 2021
|
|
|
|
|
|
|
|
|
R |
+ |
+ |
+ |
+ |
+ |
|
|
|
|
|
|
|
|
|
|
|
F |
+ |
+ |
+ |
– |
+ |
|
|
|
|
|
|
|
|
|
|
|
I |
+ |
+ |
+ |
– |
+ |
|
|
|
|
TSC1/2
|
|
Regulates mTORC1 pathway, neuronal differentiation, and Purkinje cell excitability |
|
+ |
+ |
+ |
+ |
+ |
|
R |
+ |
+ |
+ |
+ |
+ |
|
– |
|
D-Cycloserine, Fenobam, SCH-23390, SCH-39166, Rapamycin |
|
Normand et al., 2013; Tsai et al., 2012
|
|
UBE3A
|
|
Regulates neuronal homeostatic synaptic plasticity |
|
+ |
+ |
+ |
+ |
+ |
|
R |
+ |
+ |
+ |
– |
+ |
|
Reinstatement of Ube3a in GABAergic neurons |
|
Cbln1 expression; THIP; Pamin |
|
Krishnan et al, 2017; Xu et al, 2018
|
|
Non-syndromic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NLGNs
|
|
Regulates the formation of hippocampal neurons and post-glutamatergic synapse proteins |
|
+ |
+ |
+ |
+ |
+ |
|
R |
+ |
+ |
+ |
+ |
+ |
|
Nlgn3,shRNAs against Nlgn1,shRNAs against Nlgn2,DIO-NL3 transgene in nucleus accumbens,Optogenetic activation of Pvalb interneurons, Nlgn3 reexpression |
|
ETC-168, ACEA, HU-210, Quinpirole, URB597 |
|
Camacho et al., 2014; Kolozsi et al., 2009; Sledziowska et al., 2020
|
|
NRXNs
|
|
Encodes neuronal transmembrane protein; interacts glial cells |
|
+ |
+ |
+ |
+ |
+ |
|
R |
+ |
+ |
+ |
+ |
+ |
|
– |
|
– |
|
Etherton et al., 2009; Tromp et al., 2021
|
|
|
|
|
|
|
|
CHD8
|
|
Controls epigenetic and transcript regulation; affects brain phenotype |
|
+ |
+ |
+ |
+ |
+ |
|
R |
+ |
+ |
+ |
– |
+ |
|
Human CHD8; stabilized Ctnnb1(S37A) |
|
CPI-455; Oxytocin |
|
Kunkel et al, 2018; Platt et al, 2017; Sugathan et al, 2014
|
|
|
|
|
|
|
|
|
F |
– |
– |
– |
– |
– |
|
|
|
|
POGZ
|
|
Regulates neuronal development |
|
+ |
+ |
+ |
+ |
+ |
|
R |
+ |
+ |
+ |
– |
– |
|
– |
|
NBQX; Oxytocin; Perampanel |
|
Matsumura et al, 2020; Suliman-Lavie et al, 2020; White et al, 2016
|
|
ANK2
|
|
Affects axonal branching; regulates postnatal development of excitatory synapses |
|
+ |
+ |
+ |
– |
– |
|
R |
+ |
+ |
+ |
– |
– |
|
– |
|
– |
|
Iossifov et al, 2014; Sztainberg et al, 2016
|
|
MIR137
|
|
Regulates neuronal gene expression and neurogenesis |
|
+ |
+ |
+ |
+ |
+ |
|
R |
+ |
+ |
+ |
– |
– |
|
Ablation of Pde10a |
|
Papaverine |
|
Cheng et al., 2018
|
|
16p11.2
|
|
Controls prefrontal connectivity; endothelium-dependent structural and functional neurovascular |
|
+ |
+ |
+ |
+ |
+ |
|
R |
+ |
+ |
+ |
+ |
+ |
|
– |
|
– |
|
Portmann et al, 2014; Yin et al, 2021
|
|
|
|
|
|
|
|
|
F |
– |
– |
– |
– |
– |
|
|
|
|
|